FDA delays decision on approval of Bristol Myers' CAR-T

outside of building
The FDA's delayed decision on Bristol Myers Squibb's CAR-T cell therapy has implications for people who owned Celgene stock at the time of its takeover by Bristol Myers. (Bristol Myers Squibb)

The FDA has delayed its decision on whether to approve Bristol Myers Squibb’s CAR-T cell therapy by three months. Bristol Myers attributed the delay to its submission of additional information upon the request of the FDA.

Lisocabtagene maraleucel, also known as liso-cel, is one of the CAR-T therapies that originated at Juno Therapeutics and ended up at Bristol Myers through its takeover of Celgene. In February, the FDA granted priority review to a filing for approval of the anti-CD19 CAR-T, setting Bristol Myers up to receive an approval decision from the agency by mid-August.

The FDA has now tossed out that target action date. Instead, the agency is now aiming to make a decision on whether to approve liso-cel in adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies by mid-November.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

Bristol Myers filed for FDA approval after linking liso-cel to a 53% complete response rate. The data suggested liso-cel can compete against Gilead’s Yescarta and Novartis’ Kymriah, but the original filing lacked some information the FDA wanted to see. The FDA responded to the gap by requesting more information, which, when filed, constituted a major amendment and led the agency to seek more time to review the application.

The timing of the approval has implications for people who owned Celgene stock at the time of its takeover by Bristol Myers. To seal the deal, Bristol Myers agreed to pay Celgene stockholders $9 per share if ozanimod and liso-cel won FDA approval by the end of 2020, and ide-cel received authorization from the agency by the end of March 2021. 

Ozanimod won approval in March, shifting focus to whether the FDA will authorize the cell therapies by the deadline. The revised liso-cel PDUFA date is before the deadline, and Bristol Myers said it is “committed to working with FDA” to achieve the approvals needed to trigger payments. However, the delay means there is now little wiggle room in the event of further setbacks.

The increased risk of Bristol Myers failing to win approval in time was reflected in trading of the asset that entitles holders to the payout. In premarket trading, the value of the asset fell 14%, dragging its price down to $3.80, well below the $9 it will be worth if Bristol Myers wins all three approvals by the deadlines. 

Suggested Articles

Singapore is planning to outfit each of its 5.7 million residents with a simple wearable device to track people who have been exposed to COVID-19.

The agency delivered its first batch of antibody test results in May, covering a dozen products independently evaluated by the NIH and CDC.

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.